Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141.
Gillison ML, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington KJ, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Jayaprakash V, Wei L, Ferris RL.
Gillison ML, et al. Among authors: licitra l.
Oncologist. 2022 Mar 4;27(2):e194-e198. doi: 10.1093/oncolo/oyab036.
Oncologist. 2022.
PMID: 35641218
Free PMC article.